Venus Remedies Stock Screener | Share Price & Fundamental Analysis
VENUSREM
Pharmaceuticals
Share Price NSE
₹756.05
▲
51.20 (7.26%)
Share Price BSE
₹755.25
▲
51.45 (7.31%)
Track Venus Remedies share price live with TickJournal's free stock screener.
Analyze Venus Remedies share price history trends and compare 52-week high low
levels.
Calculate VENUSREM stock fair value using fundamental analysis and view live share price charts.
Determine Venus Remedies share intrinsic value and compare it with current VENUSREM share price.
Record your Venus Remedies trades in TickJournal's free trading journal and track your portfolio performance.
Venus Remedies Market Cap
₹898.80 Cr.
VENUSREM P/E Ratio (TTM)
11.99
EPS (TTM)
₹33.90
Dividend Yield
-
Debt to Equity
0.04
VENUSREM 52 Week High
₹756.05
Venus Remedies 52 Week Low
₹428.15
Operating Margin
15.00%
Profit Margin
10.40%
VENUSREM Revenue (TTM)
₹202.00
EBITDA
₹36.00
Net Income
₹21.00
Total Assets
₹716.00
Total Equity
₹561.00
Venus Remedies Share Price History - Stock Screener Chart
Screen VENUSREM historical share price movements with interactive charts. Analyze price trends and patterns.
Venus Remedies Company Profile - Fundamental Screener
Screen Venus Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for VENUSREM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE411B01019
Venus Remedies Balance Sheet Screener
Screen VENUSREM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 716 | 627 | 601 | 580 | 556 | 644 | 733 | 751 | 765 | 843 |
| Current Assets | 452 | 360 | 323 | 278 | 234 | 294 | 265 | 260 | 259 | 277 |
| Fixed Assets | 229 | 219 | 216 | 241 | 262 | 289 | 364 | 389 | 406 | 453 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 19 | 60 | 58 | 47 | 58 | 96 | 137 | 159 | 180 | 212 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 561 | 488 | 460 | 440 | 400 | 323 | 333 | 362 | 389 | 438 |
| Share Capital | 13 | 13 | 13 | 13 | 12 | 12 | 12 | 12 | 12 | 11 |
| Reserves & Surplus | 548 | 474 | 447 | 427 | 374 | 311 | 320 | 350 | 376 | 426 |
Venus Remedies Income Statement Screener - Profit & Revenue Analysis
Screen Venus Remedies income statement and profit fundamentals.
Analyze VENUSREM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Venus Remedies share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 202 | 141 | 195 | 183 | 199 | 110 | 178 | 189 | 159 | 97 | 171 | 146 | 145 | 145 | 142 |
| Expenses | 166 | 122 | 162 | 143 | 176 | 97 | 163 | 159 | 131 | 85 | 150 | 131 | 137 | 129 | 127 |
| EBITDA | 36 | 19 | 33 | 40 | 23 | 13 | 16 | 30 | 28 | 13 | 21 | 14 | 8 | 16 | 15 |
| Operating Profit % | 15.00% | 11.00% | 16.00% | 21.00% | 10.00% | 10.00% | 4.00% | 10.00% | 16.00% | 11.00% | 11.00% | 8.00% | 4.00% | 10.00% | 9.00% |
| Depreciation | 5 | 6 | 6 | 7 | 6 | 6 | 6 | 5 | 8 | 8 | 6 | 7 | 8 | 8 | 9 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 31 | 13 | 27 | 34 | 18 | 7 | 9 | 25 | 20 | 5 | 14 | 8 | 0 | 8 | 6 |
| Tax | 10 | 3 | 6 | 8 | 7 | 6 | 6 | 5 | 9 | 4 | 4 | 1 | 0 | 1 | 0 |
| Net Profit | 21 | 10 | 20 | 26 | 11 | 1 | 4 | 20 | 11 | 1 | 10 | 7 | 0 | 7 | 5 |
| EPS | 15.71 | 7.18 | 15.06 | 19.14 | 7.86 | 0.92 | 2.63 | 14.66 | 8.27 | 0.88 | 7.44 | 5.13 | 0.17 | 5.16 | 3.99 |
Venus Remedies Cash Flow Screener - Liquidity Fundamentals
Screen VENUSREM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 86 | 37 | 37 | 41 | 132 | 78 | 45 | 31 | 59 | 47 |
| Investing Activities | -77 | -9 | -58 | -17 | 57 | -5 | -11 | 9 | -18 | 3 |
| Financing Activities | -1 | -1 | -1 | -10 | -162 | -73 | -35 | -39 | -44 | -46 |
| Net Cash Flow | 9 | 28 | -22 | 14 | 27 | 0 | -1 | 0 | -4 | 4 |
Venus Remedies Shareholding Pattern Screener
See Venus Remedies shareholding pattern with promoter, FII, and DII holdings.
Check Venus Remedies promoter holding and ownership changes for VENUSREM on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| FII Holding | 1.34% | 2.24% | 1.86% | 2.26% | 1.48% | 1.06% | 1.18% | 1.11% |
| DII Holding | 0.00% | 0.11% | 0.75% | 1.03% | 0.15% | 0.15% | 0.15% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 46.81% | 47.70% | 45.30% | 45.16% | 46.89% | 46.25% | 45.31% | 45.42% |
| Other Holding | 10.09% | 8.19% | 10.33% | 9.80% | 9.73% | 10.78% | 11.61% | 11.71% |
| Shareholder Count | 19,982 | 19,307 | 17,725 | 18,606 | 19,913 | 19,614 | 19,557 | 19,771 |
Venus Remedies Share Dividend Screener - Share Yield Analysis
Check Venus Remedies dividend history with payout and yield data.
View Venus Remedies dividend details including ex-dates and amounts for VENUSREM stock.
Venus Remedies Stock Index Membership
See which indices include Venus Remedies stock.
Check VENUSREM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Venus Remedies Market Events Screener - Corporate Actions
Get Venus Remedies corporate actions including splits, bonuses, and buybacks.
Check Venus Remedies stock events that may affect VENUSREM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 0.93% | ||
| 2026-01-29 | 2026-01-29 | Quarterly Result Announcement | NA | -3.15% |
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | 1.78% |
| 2025-08-22 | 2025-08-22 | Annual General Meeting | NA | 14.50% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | -2.92% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 3.36% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | -1.96% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -0.66% |
Venus Remedies Competitors Screener - Peer Comparison
Screen VENUSREM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 416,764 | 39.09 | 54,729 | 9.71% | 10,980 | 55.50 |
| Divis Laboratories | 170,126 | 69.29 | 9,712 | 18.67% | 2,191 | 57.58 |
| Torrent Pharmaceuticals | 146,659 | 65.55 | 11,539 | 6.99% | 1,911 | 65.06 |
| Cipla | 108,904 | 24.19 | 28,410 | 7.12% | 5,291 | 47.64 |
| Dr Reddys Laboratories | 107,359 | 19.93 | 33,741 | 16.73% | 5,725 | 55.60 |
| Lupin | 105,151 | 22.74 | 22,910 | 13.74% | 3,306 | 66.87 |
| Mankind Pharma | 92,782 | 52.20 | 12,744 | 20.90% | 2,007 | 63.52 |
| Zydus Life Science | 92,745 | 18.78 | 23,511 | 18.55% | 4,615 | 55.01 |
| Aurobindo Pharma | 70,881 | 20.37 | 32,346 | 9.43% | 3,484 | 58.41 |
| Alkem Laboratories | 67,429 | 28.38 | 13,458 | 3.70% | 2,216 | 51.36 |
Venus Remedies Company Announcements - News Screener
Screen VENUSREM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-01-29 | Unaudited Standalone And Consolidated Financial Results As On 31St December 2025 | View |
| 2026-01-29 | Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th January 2026 | View |
| 2026-01-22 | Venus Remedies Awarded With Rs. 117750000 Incentive Under The PLI Scheme. | View |
| 2026-01-19 | Board Meeting Intimation for The Meeting Of Board Of Directors Is Scheduled To Be Held On 29Th January 2026. | View |
| 2026-01-13 | Updation On UIDN For Financial Results As On 30Th September 2025 | View |
| 2026-01-08 | Grant Of Marketing Authorisation In Indonesia | View |
| 2026-01-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-12-26 | Copy Of Newspaper Notice Pertaining To Physical Transfer Of Shares. | View |
| 2025-12-23 | Closure of Trading Window | View |
| 2025-12-13 | Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited. | View |
| 2025-12-12 | Shares Re-Lodged For Transfer Cum Demat Pursuant To SEBI Circular No. SEBI/HO/MIRSD/MIRSD-Pod/P/CIR/2025/97 Dated July 2 2025 For The Period July 7 2025 To November 30 2025 | View |
| 2025-12-08 | Venus Remedies Marks Completion Of AMR Licensing Milestones With Final ?11 Crore Payment | View |
| 2025-12-01 | Update On Resolution Of Income Tax Matters And Elimination Of Contingent Liability. | View |
| 2025-11-28 | Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited | View |
| 2025-11-20 | Clarification On Movement In Volume | View |
| 2025-11-20 | Clarification sought from Venus Remedies Ltd | - |
| 2025-11-17 | Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-10 | Unaudited Financial Results As On 30Th September 2025 | View |